.jpg "Neos Therapeutics (NASDAQ: NEOS)")
Today, the CFO of Neos Therapeutics (NEOS), Richard Eisenstadt, bought shares of NEOS for $10.8K.
Following this transaction Richard Eisenstadt’s holding in the company was increased by 13.35% to a total of $86.62K. In addition to Richard Eisenstadt, 2 other NEOS executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Neos Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $12.5 million and GAAP net loss of $12.7 million. In comparison, last year the company earned revenue of $6.7 million and had a GAAP net loss of $16.26 million. Currently, Neos Therapeutics has an average volume of 335.6K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $11.67, reflecting a 472.1% upside. Starting in November 2018, NEOS received 4 Buy ratings in a row.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30,1994 and is headquartered in Grand Prairie, TX.
